QPPV.COM KNOWLEDGE ASSESSMENT

Crizanlizumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Crizanlizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A quality reviewer is assessing a serious case of apparent thrombocytopenia after crizanlizumab. Which documentation would best demonstrate an adequate medical review?

The original automated count only The preferred MedDRA term without supporting laboratory information Collection tube type, time to analysis, evidence of clumping, repeat citrate count, smear findings and bleeding phenotype A statement that thrombocytopenia is a known event without further assessment

Question 2 of 10 Why is hydroxyurea use an important variable in assessing crizanlizumab efficacy or safety cases?

Hydroxyurea determines whether crizanlizumab can bind P-selectin Hydroxyurea can influence crisis frequency, haematological parameters and disease trajectory, affecting interpretation of outcomes Hydroxyurea prevents all infusion-related reactions Hydroxyurea is used only to correct platelet-count assay interference

Question 3 of 10 Which follow-up approach is most appropriate for suspected crizanlizumab-associated thrombocytopenia based only on an EDTA automated count?

Immediately classify the case as confirmed biological thrombocytopenia Repeat testing promptly using a citrate-containing tube and consider a peripheral smear Discard the laboratory result because all low counts in sickle cell disease are expected Repeat the same EDTA test only after the next treatment cycle

Question 4 of 10 Why should a global safety database retain country or region and exposure date for crizanlizumab cases?

To determine the patient's genetic ancestry for every case To distinguish applicable product information, historical EU exposure and current regional regulatory contexts To replace the need for recording dose and administration date To ensure all cases are assigned the same regulatory status

Question 5 of 10 Why should infusion-related reactions be analysed by dose number and latency?

Early-dose clustering and timing may reveal clinically meaningful administration-related patterns Dose number has no relevance for biological medicines Latency is relevant only for delayed genetic effects Analysing all administrations together always improves causal inference

Question 6 of 10 Which operational control would most directly reduce misclassification of pain during crizanlizumab administration?

Capture infusion date, dose number, onset relative to infusion, associated symptoms, infusion actions and response Record only the final diagnosis assigned at discharge Exclude all pain reports occurring within 24 hours of dosing Require every pain event to be classified as a vaso-occlusive crisis

Question 7 of 10 What is the key pharmacovigilance concern when an automated analyser reports a low platelet count after crizanlizumab exposure?

Crizanlizumab always causes clinically significant immune thrombocytopenia The result may reflect platelet clumping and analytical interference rather than true thrombocytopenia Low platelet counts are expected and should never be investigated The result proves that the patient has splenic sequestration

Question 8 of 10 Which statement accurately describes the current regional regulatory situation presented in the article?

The medicine is globally withdrawn because the EU authorisation was revoked The EU authorisation was revoked, while current U.S. records continue to identify an active biologics licence The U.S. licence was revoked and the EU authorisation remains fully active Neither region has ever authorised crizanlizumab

Question 9 of 10 Which conclusion best captures the benefit-risk lesson from crizanlizumab's lifecycle?

A stable known safety profile guarantees a stable benefit-risk balance Benefit-risk can worsen when confirmatory efficacy evidence reduces confidence in benefit, even without a major new safety signal Only new adverse reactions can justify regulatory reassessment Mechanistic plausibility prevents later changes to regulatory conclusions

Question 10 of 10 Which statement best explains why the EU authorisation was conditional initially?

The medicine had no clinical efficacy data at the time of authorisation The available evidence supported earlier access but remained incomplete and required confirmatory evidence Conditional authorisation is used only for medicines with laboratory interference The authorisation was conditional because intravenous medicines cannot receive standard approval

Crizanlizumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings